The additional funding will be used to advance development of Repositive’s platform as the company prepares to launch and further develop premium services for enterprise users in pre-clinical research. With the Repositive services researchers and research organisations can save both time and resources by streamlining and simplifying their data access workflows.
Repositive raised £500,000 from Amadeus Capital, Seedcamp, ClearlySo and Cambridge Angels in a funding round including biotech ‘super angel’ Jonathan Milner. London-based Seedcamp came in as a new investor in this round providing tailored business support in addition to their funding to grow and scale Repositive.
With the additional seed funding now raised, Repositive will scale up both user capacity and professional services on the Repositive platform, before starting a Series A fundraising in 2016.
Fiona Nielsen, CEO of Repositive, said: “This additional seed funding will bring us to public launch of the Repositive platform to build upon our popularity and success with beta users.”
New features will include premium services both for enterprise and non-enterprise users supporting time-saving workflows and improved tools for assessing data quality and availability from both public and private data providers.
“We have a strong and growing user base and with this funding we will be able to deliver an improved platform and additional services for all of our users. The better we can serve our user community, the more successful our mission to enable efficient and ethical data access for the benefit of patients,” added Fiona.
Pierre Socha, Investment Manager at Amadeus Capital said: “Amadeus Capital is delighted to support Repositive in its quest to help transform genomics into a mainstream clinical tool. The sharp increase in computational power, limitations in data storage and the constantly growing demand for actionable and personalised healthcare information is bringing the sharing economy into the labs, connecting researchers and building the foundations of broader platforms. Repositive has all the attributes of the digital hubs that will form the core of the ecosystem. “
Gary Stewart, Director of Wayra UK, part of Telefonica Open Future, which has supported Repositive through the Wayra startup accelerator program said: “I'm really proud of Fiona. She's an amazing entrepreneur with a big vision and a take-no-prisoners attitude. That is only confirmed by the quality of the new investors that she has brought to the table. And of top of it all, she has a social mission that could potentially change the world. You can't get much better than that!"
Repositive has developed a web based platform which will allow scientists to quickly and easily access human genomics research data from a range of global sources and initiate data collaborations with both colleagues and external collaborators. The Repositive platform is in beta testing and welcoming partners in academia and industry for genomics R&D.
Repositive are experts in the provision of efficient access to genomic data. Through their platform, researchers and scientists are able to quickly and easily access data from a range of global sources, and securely share with colleagues both internal and external. Through the platform, researchers are also able to use the community to identify more relevant data, feedback and improve the metadata associated with it. From their headquarters in Cambridge, the Repositive team of experts in data management and its most effective use, also offer a range of services to corporate customers who require larger scale enterprise solutions.
www.repositive.io
*******
For further information, please contact:
Tony Stephenson
Exitus Communications
Tel: +44 (0)7899 796655
Email: tony@exituscommunications.co.uk
___________________________________________________________
Repositive secures further seed funding
2 February 2016
Repositive, a software company developing novel tools to improve access to genomic research data, has secured £500,000 of additional seed funding, as the company prepares to launch an enterprise product as part of their global hub for genomic data access.